HIA-a24 Gen Allece At Peripheral Blood Samples And Nasopharyngeal Cytobrush In Nasopharyngeal Carsinoma Patients In Makassar by Savitri, Eka et al.
Contents lists available at BioMedSciDirect Publications
Journal homepage: www.biomedscidirect.com
International Journal of Biological & Medical Research 
Int J Biol Med Res. 2014; 5(3): 4350-4354
HIA-a24 Gen Allele At Peripheral Blood Samples And Nasopharyngeal 
Cytobrush In Nasopharyngeal Carcinoma Patients In Makassar
a b c d
Eka Savitri *, Freddy George Kuhuwael , Abdul Qadar Punagi , Imelda Gunawati Agus
a,b,c
 Department of Ortholaryngology, Faculty of Medicine,  Hasanuddin University, Kampus Tamalanrea, Jl. Perintis Kemerdekaan Km.10, Makassar, South Sulawesi, Indonesia.
A R T I C L E I N F O A B S T R A C T
Keywords:
Epstein - Barr virus
Nasopharyngeal
Carcinoma
HLA - A24
Gene. 
Original Article
Nasopharyngeal cancer (NPC) is a malignancy that is highly associated with Epstein - Barr 
virus infection (EBV), highly oncogenic, easily transmitted through saliva and is a 
multifactorial genetic disease with endemic character. EBV infection will cause an immune 
response in the patient themselves to recognize and eliminate foreign antigens which is 
associated with the ability of the antigen in presenting HLA molecules to cytotoxic T cells. Some 
of the genes under study which are genes that influence the occurrence of NPC are HLA genes. 
Aims: This study aims to determine the presence of the HLA- A24 allele in peripheral blood 
samples and nasopharyngeal cytobrush NPC patients in Makassar. Methods: The study design 
was a cross sectional analytic observational test of Fischer's Exact test on 21 samples of NPC 
patients who come in Dr. Wahidin Sudirohusodo Hospital. The examination was conducted by 
BOOM'S method for DNA isolation, and followed by PCR with primers forward and reverse HLA 
- A24. Result: The results showed the presence of the HLA allele A-24 in peripheral blood 
samples (37.5%) and nasopharyngeal cytobrush (42.9%) and stated that by performing the 
same method for taking specimen and examination, HLA-A24 existing in nasopharyngeal 
cytobrush was also found in peripheral blood. Conclusion:  It is concluded that the HLA A-24 
was obtained in patients with NPC in Makassar.
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Nasopharyngeal cancer (NPC) is a malignant epithelial 
neoplasm that occurs in upper tract autodigestive and a 
multifactorial genetic disease with endemic character. There are 
approximately 80,000 new cases each year with the highest 
incidence of 2500 cases in South China per year. The highest 
incidence of NPC is in the Mongoloid race with a fairly high 
frequency in South China, Hong Kong, Vietnam, Thailand, Malaysia, 
1,2,3.
Singapore and Indonesia
NPC is in the 4th rank among all cancers in Indonesia after 
uterine, breast, and skin cancer, with incidence of 4.7 per 100,000 
population of DR.Wahidin Sudirohusodo Hospital reported in 10-
years period (2000-2009) and there were 362 cases (57.28%) of 
4,5
the malignant tumors of head and neck .
Viruses that play a role in increasing the risk of NPC are the 
Epstein Barr Virus (EBV). After EBV infects B lymphocytes, it could 
be latent and persistent for life in the host6. In some researches, the 
presence of EBV DNA from patients' peripheral blood samples 
is also found. This shows how an EBV avoids the immune system of 
7
the human body and is stabilized at lymphocytes B6, .
B cells infected by EBV will express some latent antigens such 
as LMP1 and LMP2 (LMP2A and LMP2B)8,9,10. LMP2A is a latent 
antigen expressed in B lymphocytes that are infected with EBV.   
8,10,12,13
One of the most suspicious genetic factors is the HLA genes . 
These genes are inherited through heterozygous process and are 
co-dominant. As a result, groups with particular HLA will face the 
risk of certain diseases.  Some diseases are presumably related to 
HLA, so people with certain diseases will have specific HLA 
14,15
gene .
 According to research on Southeast Asian and Caucasian 
17,18
populations, HLA - A24 and HLA - A2 are commonly found .  
Indigenous Indonesian people who have HLA - A24 possess higher 
possibility to NPC19.  According to Middleton et al. (2003), allele 
HLA- A2402 is allele of the HLA - A24 gene that is widely available 
19
in Asian populations . Immunogenetic studies in Jakarta in 1997 
found HLA - A24 and HLA - B63. Both class I antigen phenotypes 
are suspected as a causative factor for the indigenous Indonesian 
20
NPC . 
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This study aims to determine the presence of the HLA- A24 
allele in peripheral blood and nasopharyngeal cytobrush in NPC 
patients in Makassar.     
This is an observational analytic study.  NPC patients who agree 
to follow this study were upheld by histopathologic examination. 
Venous blood was taken and brushed with guidance of 
nasoendoscopy nasopharynx.  The study was conducted at 
Dr.Wahidin Sudirohusodo Hospital Makassar and Biomolecular 
Engineering Laboratory Faculty of Medicine in October - November 
2013. The study population was patients with NPC who came to the 
ENT clinic at Dr.Wahidin Sudirohusodo Hospital Makassar for two 
months. Sampling was conducted by consecutive sampling. 
Inclusion criteria were patients with NPC based on the results of 
histopathological examination included in the study that were 
willing to sign a statement to participate in the study after receiving 
an explanation (informed consent). Exclusion criteria were patients 
uncooperative and refused to participate in this study.
Patients with inclusion criteria and agreed to participate in this 
study, their blood samples were taken from venous blood samples 
and then brushing nasopharyngeal guided endoscopic 
visualization. Further isolation of DNA was done through BOOM'S 
method. Subsequently, PCR with forward and primary reserve for 
HLA-A24 with the amount of product 464 bp was performed.
During October to December 2013 has done the research to see 
HLA-A24 gene allele from peripheral blood and nasopharyngeal 
cytobrush in 21 patients with NPC.  
Characteristics of the study sample are presented in Table 1. 
Based on patient age nasopharyngeal carcinoma, the most in the 
range of 40-49 years as much as 38.0%. 16 males (76.2%) and 5 
women (23.8%) with a ratio of 3.2:1 consists of 9 Bugis people 
(42.8%), 5 Makassar people (23.8%), and  1 person for all other 
tribes of South Sulawesi (4.7%).
Histopathological distribution of NPC patients according to 
WHO obtained showed the highest type III is 17 people (80.9%), 
WHO type II by 4 people (19.1%), and WHO type I obtained in this 
study can be seen in Table 2.
PCR results of peripheral blood samples show DNA bands 
appeared on several samples with varying thickness and led to 6 
samples (W2, W6, W8, W10, W12, W16) of 16 samples (37.5%) and 
9 samples (B02, B04, B06, B08, B10, B12, B16, B19, B20) of 21 
samples (42.9%) in nasopharyngeal cytobrush.
Based on statistical tests (Fischer's Exact test) in 16 paired 
samples, it suggests that HLA-A24 presenting in 100% of 
nasopharyngeal cytobrush samples was also found in the 
peripheral blood of NPC patients and HLA-A24 contained in 
peripheral blood was also found in the nasopharynx cytobrush.
Materials and Methods
Brush of HLA Positive
Negative
6
0
0
10
HLA Blood
Positive Negative
Patients
Table 3. Comparison of HLA-A24 existing in peripheral 
blood samples and nasopharyngeal cytobrush
Type I   (carcinoma of squamosa cell with 
ceratinized)
TypeII   (Differentiated carcinoma with no ceratinized)
Type III (Undifferentiated    carcinoma/ anaplastic)
0
4
17
0
19,1
80,9
Histopathology 
result  (WHO)
Patients %
Table 2. Distribution of patients by histopathology test 
(WHO Types)
Table 1. Characteristic of the study samples
Sex
    Men
    Women
Age
    < 20
    20-29
    30-39
    40-49
    50-59
>60
Tribe
    Bugis
    Makassar
    Toraja
    Bali
    Buton
    Ternate
    Luwuk Banggai
    Kaili
16
5
0
2
1
8
5
5
9
5
1
1
1
1
1
1
76,2
23,8
0
9,5
4,7
38,0
23,8
23,8
42,8
23,8
4,7
4,7
4,7
4,7
4,7
4,7
Characteristic Patient %
Results
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Figure 1. The results of HLA-A24 PCR in peripheral blood 
samples
Graph 1. Evaluation of HLA-A24-positive samples by tribe
Discussion
Graph 2. Evaluation of HLA-A24-positive samples by 
histopathology
Figure 2. The results of HLA-A24 PCR in cytobrush 
nasofaring samples
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Graph 1
In the evaluation of 21 samples of peripheral blood and 
nasopharyngeal cytobrush, it is found that most HLA-A24 positive 
at 4 samples in Bugis tribe (19%), 2 samples in Makassar tribe 
(9%), 1 sample in Mandar tribe (4%), and 2 samples beyond South 
Sulawesi (9%).
Graph 2.
Based on Graph 2, it can be seen that  7 of the 21 samples 
(33.3%) were positive for HLA-A24 with WHO type III and 2 
samples (9%) with WHO type II.  
In the study of 16 peripheral blood samples and 21 samples of 
nasopharyngeal cytobrush, it is found that there are more men 
(76.2%) compared to women (23.8%) with a ratio of 3.2 : 1 , while 
on age and ethnicity of Nasopharyngeal Carcinoma patients , in 
which most of them is in the range of 40-49 years by 38.0 %, 
consisting of 9 Bugis people (42.8%) and 5 Makassar people 
(23.8%).
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Distribution of NPC patients according to WHO histopathology, 
type III is found to be the highest that consists of 17 people (80.9%). 
According to Pieter (2013) in Makassar, from 50 patients with NPC, 
WHO type III is obtained by 82.36 % 21.
The presence of HLA - A24 picture of DNA bands in 6 of 16 
samples of patients with NPC are similar to those obtained by Islami 
(2011) in Jogjakarta. The study also found the presence of HLA - 
A2402 in peripheral blood samples of patients with NPC22. 
Likewise, the research on immunogenetic in Jakarta in 1997 found 
HLA - A24 and HLA - B63, as well as a research conducted by 
Judajana (2007) which supports HLA - A24 , HLA - A2 and HLA - A11 
HLA class, which is the main target as a genetic marker systems 
20,23
immune to the NPC .
Cytobrush samples also obtained presence of HLA - A24, 9 
samples from 21 patients with NPC sample. Moningka's research 
(2012) also obtain HLA - A24 in cytobrush samples of nasopharynx. 
Based on these studies, DNA bands in some samples of peripheral 
blood and cytobrush suggests the possibility of a few virus peptide 
24
or latent antigens are not amplified in the examination .
 According to Munir (2007), the presence of susceptibility genes 
and protective alleles are different at each location and ethnicity, 
allegedly due to the binding molecule and peptide epitopes of 
different renderers. In addition it is also due to the different 
sampling, a different distribution of HLA genes in each population 
and due to the strong influence of environmental factors on the 
25,26
incidence of NPC in these locations .
Based on statistical tests, the presence of HLA - A24  that are in 
cytobrush 100% can also be found in peripheral blood samples. 
This indicates the presence of HLA - A24 in NPC tissues can also be 
found or represented through peripheral blood samples.
Tribal evaluation of PCR positive HLA - A24 were Bugis (19 %) 
as the highest rate, then Makassar (9 %) and Mandar (4 %). 
According to Munir (2007), Indonesia's population is unique due to 
the process of racial integration and as a result of migration or gene 
flow. Some research suggests the similarity patterns of HLA genes 
with the Chinese Indonesian population. In population genetic 
studies in Jakarta, it is concluded that the HLA antigens on  
Indonesian population is classified in the group of Mongoloid25.  
Indonesia has three different Subras, namely Subras 
Paleomongoloid Proto Malays, Subras Deutro Paleomongoloid and 
27,28
Subras Proto Malanesia . Bugis and  Makassar is categorized as 
Paleomongoloid Subras Deutro Malay. Javanese population is 
categorized as Subras Paleomongoloid Malay Deutro which also get 
HLA - A 24 HLA - A2 and HLA - A1123.
 Histopathological evaluation on a sample of HLA - A24 positive 
PCR obtained WHO type III (33.3 %) and WHO type II (9 %) from 21 
samples. According to Thompson (2004), EBV has been detected in 
nasopharyngeal carcinoma in situ, before undifferentiated 
carcinoma (WHO type III ), and it also determines the progression of 
29
malignancy . This shows that EBV infection occurs before 
neoplasia. Therefore, there is no presence of the HLA relationship 
with histopathological types  but there is a confirmation about 
the presence of EBV in WHO type III which is 100 % correlated with 
EBV and reported a high incidence rate in Southeast Asia30.
EBV express latent antigens type II also produces undifferentiated 
carcinoma ( WHO type III ) . Additionally, undifferentiated 
carcinoma (WHO type III) is also caused by abnormal cytogenetic 
related to deletions in chromosome 3 short chain loci 3p25 and 
29
3p14 .
Based on this research, HLA-A24 is found in the peripheral 
blood and nasopharyngeal cytobrush. By using the technique of 
collecting samples and examination methods with Fischer Exact 
test trials, the HLA-A24 found in cytobrush were also present in the 
peripheral blood. It was concluded that the HLA-A24 can be found 
in the peripheral blood and cytobrush nasopharyngeal in patients 
with nasopharyngeal carcinoma in Makassar.
Further research needs to be done to look for other HLA alleles 
in order to find genetic risk factors in Makassar.
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